12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Reolysin: Completed Phase II enrollment

Oncolytics completed enrollment in the open-label, U.S. Phase II REO 017 trial evaluating first-line therapy with gemcitabine plus IV Reolysin every 3 weeks in 33 patients. Last year, Oncolytics reported data from the...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >